Radiosurgery guided by a special scan added to Tumor Treating Fields for recurrent glioblastoma
Compares Tumor Treating Fields with or without targeted radiosurgery in adults with recurrent glioblastoma.
Plain-language title generated from the registry record
Registry title: TTFields Plus FET-PET-Guided Stereotactic Radiosurgery Versus TTFields Alone for Recurrent Glioblastoma (Tarrget 2.0)
Key facts
- Where
- Bydgoszcz, PolandSee the site
Where in Poland
- Department of Neurooncology and Radiosurgery, Franciszek Lukaszczyk Oncology CenterBydgoszcz, PolandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Prof. Franciszek Lukaszczyk Memorial Oncology Center
- Trial code
- NCT07668869
- Record updated
- 25 June 2026
- Original description
This study evaluates whether the addition of FET-PET-guided stereotactic radiosurgery (SRS) to Tumor Treating Fields (TTFields) improves survival outcomes in patients with recurrent IDH-wildtype glioblastoma.Read full original descriptionShow less
Tumor Treating Fields (TTFields) Concomitant With Stereotactic Radiosurgery Based on FET-PET vs TTFields Alone for the Treatment of Recurrent, Glioblastoma (Tarrget 2.0)
This study evaluates whether the addition of FET-PET-guided stereotactic radiosurgery (SRS) to Tumor Treating Fields (TTFields) improves survival outcomes in patients with recurrent IDH-wildtype glioblastoma.
Patients with recurrent glioblastoma have limited treatment options and poor prognosis. TTFields is a non-invasive antimitotic therapy that has demonstrated efficacy in recurrent glioblastoma. Stereotactic radiosurgery is commonly used in selected patients with recurrent disease; however, treatment efficacy may be limited by the infiltrative nature of glioblastoma and challenges in accurate target delineation.
The study hypothesizes that combining TTFields with FET-PET-guided stereotactic radiosurgery will improve one-year overall survival compared with TTFields alone. Participants will be randomized in a 1:1 ratio to receive either TTFields plus stereotactic radiosurgery or TTFields alone.
Inclusion: Age ≥18 years; Karnofsky Performance Status ≥70; Histologically confirmed IDH-wildtype glioblastoma; First, second, or third recurrence; Radiological recurrence according to RANO 2.0 criteria; Prior radiotherapy and temozolomide treatment; At least 6 months since completion of previous radiotherapy; Contrast-enhancing recurrent lesion visible on MRI; Maximum recurrent lesion diameter ≤5 cm; Available molecular profile including IDH and MGMT status; Adequate hematologic, renal, and hepatic function; Written informed consent.
Exclusion: Previous bevacizumab treatment; Planned chemotherapy or targeted therapy after study intervention; Previous stereotactic re-irradiation within the planned treatment field; Significant psychiatric disorders; Significant unrelated neurological disease; Active intracranial hemorrhage; Uncontrolled hypertension; More than three recurrences; Implanted pacemaker, defibrillator, deep brain stimulator, or other incompatible electronic device; Pregnancy or breastfeeding; Severe renal dysfunction; Participation in another interventional study likely to interfere with this study.